Predictors of undetectable hepatitis delta virus RNA at 48 weeks after end of treatment with bulevirtide monotherapy in the MYR301 study

View Full Paper

Ask AI

Bookmark

Undetectable hepatitis delta virus RNA was maintained in a subset of patients after 48 weeks.
The analysis focuses on predictors based on data from a Phase 3 clinical trial with bulevirtide.
Patients who achieved undetectable HDV RNA at end of treatment were the primary focus of the evaluation.
Findings from this study support the potential long-term effects of bulevirtide in chronic hepatitis delta treatment.

Authors

Discussion

No takes yet. Share an insight, caveat, or question.

Phase 3 trial shows maintenance of undetectable HDV RNA in chronic hepatitis delta patients after 48 weeks, suggesting bulevirtide's effectiveness.

Aleman et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 3 trial shows maintenance of undetectable HDV RNA in chronic hepatitis delta patients after 48 weeks, suggesting bulevirtide's effectiveness.